Zentalis Pharmaceuticals (ZNTL) Assets (2019 - 2026)

Zentalis Pharmaceuticals' Assets history runs 8 years deep, the most recent figure standing at $253.1 million for Q1 2026.

• On a quarterly basis, Assets fell 34.1% year-over-year to $253.1 million in Q1 2026; TTM through Mar 2026 was $253.1 million, a 34.1% decrease from a year earlier, with the FY2025 full-year figure at $289.0 million, down 32.85% from the prior year.
• Assets fell to $253.1 million in Q1 2026 per ZNTL's latest filing, from $289.0 million in the prior quarter.
• Across five years, Assets topped out at $621.4 million in Q2 2023 and bottomed at $253.1 million in Q1 2026.
• The 5-year median for Assets is $489.3 million (2023), against an average of $460.3 million.
• Across the five-year window, Assets jumped 99.98% in 2022 and plunged 34.1% in 2026, its largest moves.
• Year by year, Assets stood at $539.3 million in 2022, then increased by 2.3% to $551.7 million in 2023, then decreased by 22.0% to $430.3 million in 2024, then slumped by 32.85% to $289.0 million in 2025, then decreased by 12.42% to $253.1 million in 2026.
• Per Business Quant, the three latest ZNTL Assets figures stand at $253.1 million (Q1 2026), $289.0 million (Q4 2025), and $327.2 million (Q3 2025).